Zoetis has announced VMD approval for Lenivia (izenivetmab injection), giving UK vets a new injectable option to alleviate pain associated with osteoarthritis in dogs for up to three months with a single injection.

Lenivia is the first long-acting canine anti-nerve growth factor monoclonal antibody therapy administered three-monthly.

It acts via its binding to nerve growth factor (NGF), a recognised mediator of pain and inflammation.

Julia von Gablenz, Regional President, Europe & Middle East of Zoetis, said: "Lenivia's approval marks a meaningful milestone in our continued innovation for canine osteoarthritis pain."

She added: "With Lenivia's approval, we're proud to bring UK(GB) veterinary professionals a new, long-acting option that can help alleviate osteoarthritis-associated pain and support sustained comfort with a single injection."